These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 22922230)

  • 1. Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice.
    Dumont M; Stack C; Elipenahli C; Jainuddin S; Gerges M; Starkova N; Calingasan NY; Yang L; Tampellini D; Starkov AA; Chan RB; Di Paolo G; Pujol A; Beal MF
    Hum Mol Genet; 2012 Dec; 21(23):5091-105. PubMed ID: 22922230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice.
    Dumont M; Stack C; Elipenahli C; Jainuddin S; Gerges M; Starkova NN; Yang L; Starkov AA; Beal F
    FASEB J; 2011 Nov; 25(11):4063-72. PubMed ID: 21825035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
    Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
    Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy.
    Shi Y; Yamada K; Liddelow SA; Smith ST; Zhao L; Luo W; Tsai RM; Spina S; Grinberg LT; Rojas JC; Gallardo G; Wang K; Roh J; Robinson G; Finn MB; Jiang H; Sullivan PM; Baufeld C; Wood MW; Sutphen C; McCue L; Xiong C; Del-Aguila JL; Morris JC; Cruchaga C; ; Fagan AM; Miller BL; Boxer AL; Seeley WW; Butovsky O; Barres BA; Paul SM; Holtzman DM
    Nature; 2017 Sep; 549(7673):523-527. PubMed ID: 28959956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glimepiride mitigates tauopathy and neuroinflammation in P301S transgenic mice: role of AKT/GSK3β signaling.
    Zaki MO; El-Desouky S; Elsherbiny DA; Salama M; Azab SS
    Inflammopharmacology; 2022 Oct; 30(5):1871-1890. PubMed ID: 35922737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease.
    Johri A; Calingasan NY; Hennessey TM; Sharma A; Yang L; Wille E; Chandra A; Beal MF
    Hum Mol Genet; 2012 Mar; 21(5):1124-37. PubMed ID: 22095692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice.
    Ozcelik S; Fraser G; Castets P; Schaeffer V; Skachokova Z; Breu K; Clavaguera F; Sinnreich M; Kappos L; Goedert M; Tolnay M; Winkler DT
    PLoS One; 2013; 8(5):e62459. PubMed ID: 23667480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P2X7 receptor blockade reduces tau induced toxicity, therapeutic implications in tauopathies.
    Di Lauro C; Bianchi C; Sebastián-Serrano Á; Soria-Tobar L; Alvarez-Castelao B; Nicke A; Díaz-Hernández M
    Prog Neurobiol; 2022 Jan; 208():102173. PubMed ID: 34516970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity.
    Stack C; Jainuddin S; Elipenahli C; Gerges M; Starkova N; Starkov AA; Jové M; Portero-Otin M; Launay N; Pujol A; Kaidery NA; Thomas B; Tampellini D; Beal MF; Dumont M
    Hum Mol Genet; 2014 Jul; 23(14):3716-32. PubMed ID: 24556215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic suppression of β2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies.
    Wisely EV; Xiang YK; Oddo S
    Hum Mol Genet; 2014 Aug; 23(15):4024-34. PubMed ID: 24626633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Sleep Disruption Advances the Temporal Progression of Tauopathy in P301S Mutant Mice.
    Zhu Y; Zhan G; Fenik P; Brandes M; Bell P; Francois N; Shulman K; Veasey S
    J Neurosci; 2018 Nov; 38(48):10255-10270. PubMed ID: 30322903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies.
    Rockenstein E; Ubhi K; Mante M; Florio J; Adame A; Winter S; Brandstaetter H; Meier D; Masliah E
    BMC Neurosci; 2015 Nov; 16():85. PubMed ID: 26611895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy.
    Barini E; Antico O; Zhao Y; Asta F; Tucci V; Catelani T; Marotta R; Xu H; Gasparini L
    Mol Neurodegener; 2016 Feb; 11():16. PubMed ID: 26858121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice.
    Zhang YH; Wang DW; Xu SF; Zhang S; Fan YG; Yang YY; Guo SQ; Wang S; Guo T; Wang ZY; Guo C
    Redox Biol; 2018 Apr; 14():535-548. PubMed ID: 29126071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure.
    Rockenstein E; Ubhi K; Trejo M; Mante M; Patrick C; Adame A; Novak P; Jech M; Doppler E; Moessler H; Masliah E
    BMC Neurosci; 2014 Jul; 15():90. PubMed ID: 25047000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.
    Köhler C; Dinekov M; Götz J
    Neurobiol Aging; 2013 May; 34(5):1369-79. PubMed ID: 23294633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice.
    Jiang T; Zhang YD; Chen Q; Gao Q; Zhu XC; Zhou JS; Shi JQ; Lu H; Tan L; Yu JT
    Neuropharmacology; 2016 Jun; 105():196-206. PubMed ID: 26802771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau pathology is present in vivo and develops in vitro in sensory neurons from human P301S tau transgenic mice: a system for screening drugs against tauopathies.
    Mellone M; Kestoras D; Andrews MR; Dassie E; Crowther RA; Stokin GB; Tinsley J; Horne G; Goedert M; Tolkovsky AM; Spillantini MG
    J Neurosci; 2013 Nov; 33(46):18175-89. PubMed ID: 24227726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.
    Caccamo A; Magrì A; Medina DX; Wisely EV; López-Aranda MF; Silva AJ; Oddo S
    Aging Cell; 2013 Jun; 12(3):370-80. PubMed ID: 23425014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement C3a receptor antagonist alleviates tau pathology and ameliorates cognitive deficits in P301S mice.
    Yao Y; Chang Y; Li S; Zhu J; Wu Y; Jiang X; Li L; Liu R; Ma R; Li G
    Brain Res Bull; 2023 Aug; 200():110685. PubMed ID: 37330021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.